Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D03LRU
|
|||
| Former ID |
DCL000035
|
|||
| Drug Name |
Alvespimycin hydrochloride
|
|||
| Synonyms |
Alvespimycin hydrochloride (USAN); 17-DMAG; 17-Desmethoxy-17-N,N-dimethylaminoethylamino-geldanamycin, HCl; 17-N,N-Dimethylaminoethylamino-17-demethoxy-geldanamycin, HCl; 17DMAG; 17DMAG, Alvespimycin, KOS-1022, NSC 707545, 17-DMAG
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Ovarian cancer [ICD-11: 2C73; ICD-10: C56] | Phase 1 | [1] | |
| Refractory hematologic malignancy [ICD-11: 2A85.5; ICD-10: C83.1] | Phase 1 | [1] | ||
| Therapeutic Class |
Anticancer Agents
|
|||
| Company |
Bristol-Myers Squibb; Kosan Biosci.
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C32H49ClN4O8
|
|||
| Canonical SMILES |
CC1CC(C(C(C=C(C(C(C=CC=C(C(=O)NC2=CC(=O)C(=C(C1)C2=O)NCCN(C)C)C)OC)OC(=O)N)C)C)O)OC.Cl
|
|||
| InChI |
1S/C32H48N4O8.ClH/c1-18-14-22-27(34-12-13-36(5)6)24(37)17-23(29(22)39)35-31(40)19(2)10-9-11-25(42-7)30(44-32(33)41)21(4)16-20(3)28(38)26(15-18)43-8;/h9-11,16-18,20,25-26,28,30,34,38H,12-15H2,1-8H3,(H2,33,41)(H,35,40);1H/b11-9-,19-10+,21-16+;/t18-,20+,25+,26+,28-,30+;/m1./s1
|
|||
| InChIKey |
DFSYBWLNYPEFJK-IHLRWNDRSA-N
|
|||
| CAS Number |
CAS 467214-21-7
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00089271) 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas. U.S. National Institutes of Health. | |||
| REF 2 | Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008 Jul;51(1):34-41. | |||
| REF 3 | Anti-proliferative activity of heat shock protein (Hsp) 90 inhibitors via beta-catenin/TCF7L2 pathway in adult T cell leukemia cells. Cancer Lett. 2009 Oct 18;284(1):62-70. | |||
| REF 4 | Recent advances in Hsp90 inhibitors as antitumor agents. Anticancer Agents Med Chem. 2008 Oct;8(7):761-82. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.